Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ketorolac intranasal - Assertio Therapeutics

Next Previous
Drug Profile

Ketorolac intranasal - Assertio Therapeutics

Alternative Names: Ketorolac trometamol intranasal; Ketorolac trometamol nasal spray; Ketorolac tromethamine intranasal; Ketorolac tromethamine nasal spray; ROX-828; ROX-888; Sprix

Latest Information Update: 22 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ROXRO PHARMA
  • Developer Assertio Therapeutics; OraPharma; ROXRO PHARMA
  • Class 2 ring heterocyclic compounds; Azabicyclo compounds; Benzene derivatives; Carboxylic acids; Ketones; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrroles; Small molecules
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute pain
  • Discontinued Migraine

Most Recent Events

  • 16 Jun 2026 Assertio Therapeutics has been acquired by Zydus Lifesciences
  • 08 Apr 2026 Cosette Pharmaceuticals acquires US rights for Sprix® from Assertio Therapeutics
  • 20 May 2020 Assertio Therapeutics has been merged with Zyla Life Sciences to form Assertio Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top